← 返回前沿论文

伴 MLH1 启动子高甲基化的微卫星高度不稳定子宫内膜癌的独特分子与临床特征

英文原题:Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.

PubMed 2022/10/03(内容时间) Clin Cancer Res Q1 · IF 10.9(JCR 2025)

研究概要

与胚系和体细胞 MMR-D 子宫内膜癌相比,MLH1ph 子宫内膜癌可能构成一种独特的临床病理实体,具有潜在的治疗意义。

中文摘要

目的:微卫星高度不稳定(MSI-H)子宫内膜癌由不同机制引起DNA错配修复缺陷(MMR-D)。本研究旨在描述携带MMR基因胚系或体细胞突变,或存在MLH1启动子高甲基化(MLH1ph)的MSI-H子宫内膜癌临床及遗传特征。 实验设计:在接受临床肿瘤-正常组织测序的1100余名子宫内膜癌患者中,184例为MSI-H;其原因是体细胞MMR突变、MLH1ph或致病性MMR胚系突变。采用非参数检验比较不同MMR-D组的临床病理特征、突变图谱和TIL(肿瘤浸润淋巴细胞)评分。分类变量关联使用log-rank检验;连续变量和生存分析使用Kaplan-Meier法及基于Cox比例风险模型的Wald检验。 结果:与胚系突变组(n=25)和体细胞突变组(n=39)相比,MLH1ph子宫内膜癌患者(n=120)年龄更大(P<0.001)、肥胖更多(P=0.001),确诊时疾病分期更晚(P=0.025)。MLH1ph子宫内膜癌富集JAK1体细胞突变,而胚系MMR-D子宫内膜癌则富集致病性ERBB2突变。与携带胚系或体细胞MMR突变的子宫内膜癌相比,MLH1ph肿瘤的肿瘤突变负荷及TIL评分较低(P<0.01)。单变量分析中,MLH1ph患者PFS较短,但多变量模型中仅确诊分期仍是生存预测因素。I/II期子宫内膜癌患者中,MLH1ph组两年PFS低于胚系及体细胞MMR组(70%比100%)。 结论:与胚系和体细胞MMR-D子宫内膜癌相比,MLH1ph子宫内膜癌可能构成一种独特的临床病理实体,并可能影响治疗选择。

展开英文摘要原文

PURPOSE: Microsatellite instability-high (MSI-H) endometrial carcinomas are underpinned by distinct mechanisms of DNA mismatch repair deficiency (MMR-D). We sought to characterize the clinical and genetic features of MSI-H endometrial cancers harboring germline or somatic mutations in MMR genes or MLH1 promoter hypermethylation (MLH1ph). EXPERIMENTAL DESIGN: Of > 1,100 patients with endometrial cancer that underwent clinical tumor-normal sequencing, 184 had MSI-H endometrial cancers due to somatic MMR mutations or MLH1ph, or harbored pathogenic germline MMR mutations. Clinicopathologic features, mutational landscape, and tumor-infiltrating lymphocyte (TIL) scores were compared among MMR-D groups using nonparametric tests. Log-rank tests were used for categorical associations; Kaplan-Meier method and Wald test based on Cox proportional hazards models were employed for continuous variables and survival analyses. RESULTS: Compared with patients with germline (n = 25) and somatic (n = 39) mutations, patients with MLH1ph endometrial cancers (n = 120) were older (P < 0.001), more obese (P = 0.001) and had more advanced disease at diagnosis (P = 0.025). MLH1ph endometrial cancers were enriched for JAK1 somatic mutations as opposed to germline MMR-D endometrial cancers which showed enrichment for pathogenic ERBB2 mutations. MLH1ph endometrial cancers exhibited lower tumor mutational burden and TIL scores compared with endometrial cancers harboring germline or somatic MMR mutations (P < 0.01). MLH1ph endometrial cancer patients had shorter progression-free survival (PFS) on univariate analysis, but in multivariable models, stage at diagnosis remained the only predictor of survival. For stage I/II endometrial cancer, two-year PFS was inferior for patients with MLH1ph endometrial cancers compared with germline and somatic MMR groups (70% vs. 100%, respectively). CONCLUSIONS: MLH1ph endometrial cancers likely constitute a distinct clinicopathologic entity compared with germline and somatic MMR-D ECs with potential treatment implications.

论文信息

作者
Manning-Geist BL、Liu YL、Devereaux KA、Paula ADC、Zhou QC、Ma W、Selenica P、Ceyhan-Birsoy O
第一作者单位
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.United States
通讯作者单位
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.United States
文献类型
美国 NIH 资助研究 · 非美国政府资助研究
期刊
Clinical cancer research : an official journal of the American Association for Cancer Research2022 Oct 3
原文标识
PubMed 35849120 · DOI 10.1158/1078-0432.CCR-22-0713